Navigation Links
Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax

Single-Dose Protection Observed Prior to or Up to 24 Hours After Exposure to Anthrax

TORONTO, Ontario, May 24, 2007 /PRNewswire/ -- Targanta Therapeutics Corporation announced today the results from a recent study demonstrating oritavancin as a potential therapy for treating exposure to Bacillus anthracis, the bacterium which causes anthrax, an acute infectious disease. Oritavancin, a novel semi- synthetic lipoglycopeptide antibiotic for the treatment of serious gram- positive infections, is Targanta's lead product currently in post-Phase 3 clinical development. This research was conducted and presented in partnership with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) at the American Society for Microbiology (ASM) 107th Annual General Meeting in Toronto, Ontario from May 21-25, 2007.

"We are encouraged by the research demonstrating that oritavancin may represent a potential treatment for anthrax exposure," said Thomas Parr, Ph.D., Chief Scientific Officer, Targanta Therapeutics. "This research eventually could lead to better protection for both military personnel and citizens against an anthrax attack."

Study Methods and Results:

Efficacy of Oritavancin in a Murine Model of Bacillus anthracis Spore Inhalation Anthrax

Using an aerosol-anthrax mouse model, researchers investigated oritavancin (ORI) as potential therapy for inhalational anthrax (post-exposure). In the model, mice were exposed to spores of the Ames strain of B. anthracis at seventy five times the lethal dose necessary to kill 50% of untreated mice (75 x LD50). The control group received either saline or 30 mg/kg of ciprofloxacin (CIP) intraperitoneally (within the abdominal cavity) every 12 hours for 14 days. ORI doses ranged from 0.1 to 30 mg/kg intraperitoneally every 48 hours for 14 days. Alternatively, ORI was administered intravenously from 5 to 50 mg/kg as a single intravenous dose. All
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:5/15/2008)...BONITA SPRINGS, Fla., May 15 /- Tigri...ion of a Cooperative Research and,Development Agre...NCI) to,collaborate on clinical and preclinical de... Phase I development. AFP-464 is converted to,meta... p53 activation and,apoptosis., This is part of a...
(Date:5/15/2008)...iderable Opportunity Remains for an Antiplatelet T...leeding than the Combination of Plavix/Iscover ...ion Resources, WALTHAM, Mass., May 15 /PRNewswire...g research and advisory firms for pharmaceutical a...i Lilly,s Effient offers,improvement in patient co...
(Date:5/15/2008)...p Line Data Expected soon after CEA Trial data rep... -, SAN FRANCISCO, May 15 /PRNewswire-FirstC..., a biotechnology company focused on the developme...r disease, announced today that,it has completed p...ACS),study. The ACS study is one of three Phase 2 ...
(Date:5/15/2008)... Data Presented at the 21st Annual Meeting of The ...y/Oncology (ASPHO) Meeting -, IRVINE, Calif., May...e,Company) (Nasdaq: IDMI ) today announced the pr...cess program evaluating mifamurtide (L-MTP-PE) in,...rogression of,osteosarcoma, a rare and often fatal...
Breaking Medicine Technology:Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 2IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 3IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 4IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 5IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 6The Dark Report and Siemens Introduce the Worlds First Integrated Molecular Summit 2764 1The Dark Report and Siemens Introduce the Worlds First Integrated Molecular Summit 2764 2The Dark Report and Siemens Introduce the Worlds First Integrated Molecular Summit 2764 3The Dark Report and Siemens Introduce the Worlds First Integrated Molecular Summit 2764 4BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia Hyperphosphatemia and Secondary 2760 1BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia Hyperphosphatemia and Secondary 2760 2Modified Atkins diet can cut epileptic seizures in adults 10224 1Modified Atkins diet can cut epileptic seizures in adults 10224 2Embryos Discarded During IVF Create Stem Cell Lines 10220 1Embryos Discarded During IVF Create Stem Cell Lines 10220 2
(Date:5/16/2008)... ,What this country needs is more unemployed pol... /PRNewswire-FirstCall/ -- Although nearly all,vot...portant issues" list,a looming federal budgetary ...d by any of the current presidential candidates is...S. Senate Majority Leader Bill Frist., Jousting w...
(Date:5/16/2008)... HARRISBURG, Pa., May 16 /PRNewswire-USNewswi...4, is an opportunity to highlight the dedication,o...re citizens to become,trained EMS volunteers, acco...son., This year,s theme, "EMS: Your Life is Our M...ncy is or when it occurs, EMS is there to provide,...
(Date:5/16/2008)... WASHINGTON, May 16 /PRNewswire-USNewswire/ -...ed area of the Irrawaddy delta, survivors of,Cyclo...ere problems. Many,survivors still need assistance... are creating an increasingly dire situation., "T... more help to,recover from this disaster and get b...
(Date:5/16/2008)... Appeals for Funds Focus on Millions of Chi...re/ -- The U.S. Fund for UNICEF and The,Advertisin...ute and promote,a series of national public servic...s, including Ben Stiller, Nicole Ritchie, Joel Mad... designed to help survivors of the,Myanmar cyclone...
Breaking Medicine News(10 mins):Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 3Health News:PA Secretary of Health Announces 'Emergency Medical Services Week,' May 18 - 24 2Health News:Myanmar Cyclone Survivors Face New Challenges 2Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 2Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 3
...oft drinks, on sale in Britain and France have rev...zene. The levels found// are 8 times the permissib...ing to the Food Standards Agency, involved in the ...emical, produced during partial combustion of carb...
...ision of household chores or other factors can mak...only sole factor that contribute to a woman's mari...engagement// and commitment. The following is the ... and Steven L. Nock, from the University of Virgin...
...orld Health Organization to investigate the possib...ect outbreaks of bird flu//. They are already read...s where the investigation with bird flu virus is a...ing questions in the House of Commons about the UK...
...es Secretary Michael Leavitt said that the lethal ...ich will soon infect wild birds// and domesticated...ssional panel told the senators that it's just a m...ds and possibly poultry flocks would contract the ...
Other Medicine News:Health News:High Levels Of Cancer Chemical Found In Soft Drinks 2Health News:Emotional Engagement of Husband - A Final Answer To What Women Want 2
... the best potential for quality vision with ACRYSO...ical aberration by addressing the effects of over-...without increasing edge thickness. Human corneal ...hat provides improved image quality.,MTF (mea...
...tations provide comprehensive neurological monitor...to accurately access your patients neurological st...e, and a long history of achievements, Axon System...roven record of accurate and reliable performance....
...is a cost-effective, office-based ultrasound syste...lity of our more expensive ProSound models in a co...small exam rooms., ,The SSD-3500 is also DICOM...stem (iDMS) enables easy storage and retrieval of ...
...currently developing additional assays for the blo...3.47 million to date in contract funding from the ...as been used to develop the Procleix WNV Assay. Th...centers under an Investigational New Drug Applicat...
Medicine Products: